Attached files
file | filename |
---|---|
EX-99.1 - EX-99.1 - ALKERMES INC | b85333exv99w1.htm |
Table of Contents
UNITED
STATES
SECURITIES AND EXCHANGE COMMISSION
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported): March 3, 2011
ALKERMES, INC.
(Exact Name of Registrant as Specified in its Charter)
PENNSYLVANIA (State or Other Jurisdiction of Incorporation) |
1-14131 (Commission File Number) |
23-2472830 (I.R.S. Employer Identification No.) |
852 Winter Street Waltham, Massachusetts (Address of principal executive offices) |
02451-1420 (Zip Code) |
Registrants telephone number, including area code: (781) 609-6000
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy
the filing obligation of the registrant under any of the following provisions (see General
Instruction A.2. below):
o | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |
o | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |
o | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |
o | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
TABLE OF CONTENTS
Item 7.01. Regulation FD Disclosure | ||||||||
Item 9.01. Financial Statements and Exhibits | ||||||||
SIGNATURE | ||||||||
EX-99.1 |
Table of Contents
Item 7.01. | Regulation FD Disclosure |
On March 3, 2011, Alkermes, Inc. (Alkermes), Amylin Pharmaceuticals, Inc. (Amylin), and
Eli Lilly and Co. (Lilly) announced top-line results from DURATION-6, a head-to-head study
designed to compare BYDUREON (exenatide extended-release for injectable suspension), an
investigational type 2 diabetes therapy, to daily Victoza® (liraglutide (rDNA origin)
injection).
A copy of the press release is attached hereto as Exhibit 99.1. The information set forth in
this Section 7.01, including Exhibit 99.1, shall not be deemed filed for purposes of
Section 18 of the Exchange Act, or incorporated by reference in any filing under the
Securities Act or the Exchange Act, except as shall be expressly set forth by specific
reference in such a filing.
Item 9.01. | Financial Statements and Exhibits. |
(d) Exhibits
Exhibit No. | Description | |
99.1
|
Press release issued by Alkermes, Amylin and Lilly, dated March 3, 2011, announcing topline results of DURATION-6. |
Table of Contents
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has
duly caused this report to be signed on its behalf by the undersigned hereunto duly
authorized.
ALKERMES, INC. |
||||
Date: March 3, 2011 | By: | /s/ James M. Frates | ||
James M. Frates | ||||
Senior Vice President, Chief Financial Officer and Treasurer | ||||